CD4 and cancer: This is indeed the first report characterizing CD4+ T cells specific for a cancer/testis antigen in cancer patients with spontaneous immune responses ex vivo. We found that the frequency of CD4+ T cells specific for ESO was significantly lower in patients with spontaneous immune responses as compared to that found in vaccinated patients.